PHILADELPHIA (February 27, 2025) — Fox Chase Cancer Center’s Department of Bone Marrow Transplant and Cellular Therapy (BMT) has received reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).
“We are happy to report that we have been reaccredited for another three years. This reaccreditation serves as an important indication of our qualifications in the competitive field of cellular therapy,” said Henry Chi Hang Fung, MD, FACP, FRCPE, the department’s Chair.
“Our program consistently meets and exceeds the rigorous criteria established by organizations like FACT based on the high number of transplants we perform, our level of expertise, and the support personnel available for our patients,” added Fung. “With this distinction, we know patients can feel assured that they are being treated at a facility with the highest quality care for cellular therapy.”
Founded in 1996, FACT is a nonprofit corporation co-founded by the International Society for Cell and Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy for voluntary inspection and accreditation in the field of cellular therapy. FACT promotes improvement and progress by establishing minimum standards, providing education, and inspecting and accrediting programs worldwide.
FACT accreditation indicates that an institution has met the most rigorous standards in every aspect of cellular therapy. This covers the entire spectrum of the therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release.
The BMT demonstrated compliance with the FACT-JACIE (Joint Accreditation Committee–ISCT & EBMT) International Standards for Cellular Therapy Product Collection, Processing, and Administration. This resulted in it being reaccredited for adult allogeneic and autologous hematopoietic progenitor cell transplantation, immune effector cellular therapy, cellular therapy product collection by apheresis for administration and further manufacturing, and cellular therapy product processing with minimal manipulation.
FACT-JACIE standards aim to promote improvement and progress in the fields of cellular therapy and regenerative medicine. These standards are regularly updated and defined by leading international experts based on the latest knowledge in the field of cellular therapy.
Reaccreditation is attained through evaluation of submitted documentation and onsite inspection to determine if an organization is compliant with current FACT standards. FACT is the only accrediting agency that addresses all quality aspects of cellular therapy and cord blood banking, including collection, processing, and administration.